Filing Details
- Accession Number:
- 0001062993-21-002721
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-15 17:12:38
- Reporting Period:
- 2021-03-12
- Accepted Time:
- 2021-03-15 17:12:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1616212 | Trillium Therapeutics Inc. | TRIL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1838047 | Robert Uger | C/O Trillium Therapeutics Inc. 2488 Dunwin Drive Mississauga A6 L5L 1J9 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2021-03-12 | 2,917 | $3.39 | 2,917 | No | 4 | M | Direct | |
Common Shares | Disposition | 2021-03-12 | 2,917 | $11.97 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Stock Option (Right to Buy) | Disposition | 2021-03-12 | 2,917 | $0.00 | 2,917 | $3.39 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
58,333 | 2028-11-08 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8020 USD.
- 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.